Swiss company Roche said on Tuesday that it will acquire California-based biopharmaceutical company Poseida Therapeutics at a price of $9 per share, with a total share capital value of $1 billion after completion of the acquisition. The company said shareholders will also receive non-tradable contingent rights at a price of $4 per share, with a total transaction value of up to approximately $1.5 billion. The deal is expected to close in the first quarter of 2025.

Swiss company Roche said on Tuesday that it will acquire California-based biopharmaceutical company Poseida Therapeutics at a price of $9 per share, with a total share capital value of $1 billion after completion of the acquisition. The company said shareholders will also receive non-tradable contingent rights at a price of $4 per share, with a total transaction value of up to approximately $1.5 billion. The deal is expected to close in the first quarter of 2025.